Premium
Properties of GLP‐1 agonists and their use in type 2 diabetes
Author(s) -
Chaplin Steve,
Bain Stephen
Publication year - 2016
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1430
Subject(s) - exenatide , liraglutide , dulaglutide , lixisenatide , medicine , type 2 diabetes , glucagon like peptide 1 receptor , adverse effect , glucagon like peptide 1 , pharmacology , diabetes mellitus , endocrinology , agonist , receptor
There are currently four glucagon‐like peptide‐1 (GLP‐1) receptor agonists licensed for use in the treatment of type 2 diabetes in the UK: dulaglutide, exenatide, liraglutide and lixisenatide. Steve Chaplin gives an overview of their indications, mode of administration and adverse effects, and Professor Stephen Bain discusses their current place in therapy.